Database

Startups

Main Industry
Health Care
Main Product/Service
EDEN BIOSIMILAR
Founded Year
2012
Unified Business No.
54151980
Status
Active
Number of Employees
0
Total Paid-in Capital
3,059,391,410 (NT$)
Location of Company
Taiwan , New Taipei City
Exit Status
Emerging Stock Exchange(2015)、Acquired(2022)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Introduction
Founded in 2012, Eden Biologics is an innovator in biopharmaceuticals that utilizes breakthrough engineering and process technologies to provide high quality and affordable biosimilar medicines to patients in need and a formidable CDMO player for global and regional clients. Eden has submitted IND/CTA’s to over 20+ countries/regions and has passed numerous Regulatory Audits/Inspections, including from the Taiwan FDA and EU Qualified Person (QP).
EDEN’s vision is to improve global healthcare by increasing the availability of biotechnology medicines and making them affordable for ALL in need. The individual color blocks in our logo represents the pioneering aspects of our company: innovative technologies, state-of-the-art equipment, professional leadership and experienced workforce. The resulting “E” gels these together. If you zoom out, the logo includes green hills, golden fields and a dazzling sun as we envision building a better, healthier world through EDEN.



More ↓

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention./Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases/Integrating cell therapy R&D and clinical applications through the FAST CGT platform to accelerate the development and commercialization